Young mice i jected with the carcinogen N-nitroso-N-methylurea develop thymic lymphomas 2-4 months later. We previously have shown that these tumors frequently contain an activated N-ras gene that can transform rodent fibroblasts in vitro. We report here the intron/exon structure of such an activated N-ras gene and the sequence of its four coding exons. A single nucleotide change is responsible for the transforming alteration, a C--A transversion in the first base of codon 61. Through the use of synthetic oligonucleotides as hybridization probes, we show that this tumor lacks the normal allele of the N-ras gene. The implications of this finding for oncogene dominance are discussed.
Activated oncogenes of the ras family have been found in a significant proportion ofhuman tumors and human tumor cell lines (1) (2) (3) (4) (5) (6) (7) . Two members of this gene family, Ha (Harvey) and Ki (Kirsten), had originally been described as the oncogenes of acutely transforming rat sarcoma viruses (8, 9) . A third member, N-ras, was described and first was isolated from a human neuroblastoma cell line (10) and has not been found associated with retroviruses. More recently, rodent model systems have been described in which treatment with carcinogens frequently induces tumors with activated ras genes (11) (12) (13) .
Allelic analysis of the activated oncogenes has been hampered in human and rodent tumors by the presence in most tumors of a significant fraction of normal cells. Moreover, data from the analysis of cell lines are ambiguous. On the one hand, heterozygous lines carrying one activated and one normal ras allele have been described, and the behavior of activated ras alleles in the NIH 3T3 cell-transformation assay suggests that the mutation is dominant (14, 15) . On the other hand, many tumor lines lack the normal allele of the activated ras gene (16, 17) , and in some heterozygous lines the activated allele is overexpressed (15) . The situation in tumors in vivo thus remains unclear.
We have isolated an N-ras gene activated in a carcinogeninduced mouse thymic lymphoma (18) . We report here the exonic structure ofthis mouse N-ras gene, the sequence ofits four coding exons, and the identification of the activating mutation in codon 61. This has allowed us to analyze the allelic composition in the tumor. The normal N-ras gene is absent, arguing in favor of in vivo selection against its presence during tumor development.
MATERIALS AND METHODS
Nucleic Acid Extraction and Filter Hybridization. Mammalian cell DNA was purified by the NaDodSO4/proteinase K protocol followed by phenol and phenol/chloroform/isoamyl alcohol (25:24:1, vol/vol) extractions as described (13) . DNA was digested with restriction endonucleases and the products were electrophoresed in agarose gels, transferred to nitrocellulose filters, prehybridized, hybridized, and washed by the method of Southern (19) as described in ref. 13 . Cellular RNA was obtained by the guanidinium thiocyanate method with hot phenol extractions (13) . The poly(A)+ fraction was isolated by chromatography on an oligo(dT)-cellulose column. RNA was electrophoresed in agarose/formaldehyde gels to obtain separation of the molecules proportional to their molecular weight, and the gels were processed, transferred, and washed as in ref. 13 .
DNA Restriction and Subcloning. Recombinant phages containing genomic N-ras genes and flanking DNA sequences were grown and purified by centrifugation in CsCl gradients (20) . Phage DNA digested with restriction endonucleases was fractionated by electrophoresis in agarose gels. The fragments were extracted from the gels by electroelution, purified by chromatography through an Elutip column (Schleicher & Schuell). Fragments were ligated into appropriately digested plasmid vectors, which then were used to transform Escherichia coli cells; transformants were selected by antibiotic resistance. Verification ofthe constructions was by agarose gel electrophoresis of digested DNA from plasmid "minipreps" (20) . Large quantities of plasmid DNA were prepared from cleared lysates followed by banding in CsCl gradients (20) .
Sequencing of DNA. This was carried out by both the Maxam and Gilbert (21) (21) . Appropriate choices of restriction enzymes allowed the fragments to be sequenced in both directions. For the segments sequenced by Sanger's dideoxy method the pieces were subcloned in the replicative form of M13 mp8 and/or mp9 (24) . The singlestranded phage DNA was labeled by elongating a primer with Klenow DNA polymerase in the presence of [a-32P]dATP and nonradioactive dideoxynucleotides. The products were analyzed in an 8% acrylamide/urea gel. The segments were sequenced in both directions by using either both vectors (in the case of " sticky-end" segments) or both orientations in the same vector (in the case of the blunt-end segments).
Gene Transfer. NIH 3T3 cell stocks were kept at low density and transformed by DNA-mediated gene transfer (13) , with efficiency measured by counting transformed foci after 15 days of growth in medium with a low concentration (5%) of serum.
Oligonucdeotide Hybridization. Nonadecanucleotides were synthesized (Biosearch, San Rafael, CA) complementary to codons 58 to 64 (first residue) of the normal and transforming Abbreviation: kb, kilobase(s).
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. alleles of the mouse N-ras oncogene. Samples of restrictionenzyme-digested DNAs from brains and tumors were electrophoresed in 1% agarose gel. The fragments were hybridized in the dried gel with oligonucleotides radiolabeled by treatment with polynucleotide kinase and [-32P]ATP (25) . Hybridization and washing conditions were as described (26) .
RESULTS AND DISCUSSION
Structure of the Mouse N-ras Gene. Precise location of the coding exons has been obtained through Southern blot hybridization with exon-specific probes. We used a human cDNA N-ras clone p6A, (27) (kindly supplied by M. Wigler) containing the exons II-IV to probe restriction digests of our mouse clone X3.2 N-rasT, which harbors the entire functional N-ras gene (18) . By digestion of the cDNA with Bal I, two fragments are obtained, one containing exon II and part of exon III, encoding the amino-terminal end of the product, and one containing the rest ofexon III plus exon IV, encoding the carboxyl-terminal end (27) . For exon I, low-stringency hybridization with a Ki-ras first exon-specific probe derived from a viral Ki-ras cDNA (HiHi3) (28) was used.
To confirm the localization of these exons and to define better the limits of the transcribed unit, we probed RNA from the cell line 3.2 (a 3T3 transformant with increased expression of N-ras) with different fragments of the gene. As can be seen in Fig. 1 , the two main N-ras messages are of 2.4 and 1.5 kb. Both span a region containing all coding exons. The 5' limit of the region is at least 600 bases upstream from the sequence coding for the first amino acid (unpublished results), and it extends 3' to the unique-sequence fragment Bgl ing the third coding exon was used is due to the multiple repetitive sequences in this region (18) . All of the probes detect a faint 5-kb transcript both in cell line 3.2 and in untransformed NIH 3T3 cells (13), which we presume comes from the endogenous 3T3 N-ras gene.
Sequence of the Mouse N-ras Coding Exons and Identification of the Activating Mutation. The regions of X3.2 N-rasT DNA containing coding exons were sequenced by following the strategy outlined in Fig. 1 . Since activating ras gene alterations have been found only in the first two exons, for comparison we cloned a 7.4-kb EcoRI fragment, containing exons I and II, from the normal brain DNA of the animal whose tumor yielded clone X3.2 N-rasT. We detected only a single base substitution in the first nucleotide of codon 61. It is a C-UA transversion that changes glutamine to lysine in p21, the ras gene product (Fig. 2) . This result agrees with previous reports ofhuman N-ras gene activation by a somatic mutation at codon 61 (14, 27, 29, 30) and contrasts with the predominance of codon-12 mutations in Ha-and Ki-ras (31) .
Of the 567 nucleotides that make up the N-ras coding sequence, only 51 are altered between the normal mouse and human genes, and only three of these alterations affect the predicted amino acid sequence of the N-ras-encoded protein.
All three amino acid substitutions fall in the sequence encoded by exon IV, the segment ofthe protein that was most variable in previous comparisons between species and/or between the products of ras homologs (27) .
Intron/exon junctions have been deduced by homology to the human sequence (27) . All seem to comply with the consensus sequences described, 6 or 7 bases inside the intron, although there are minor differences in these homologous regions with the human N-ras gene (27) (Fig. 2) . We had to confirm that the alteration in codon 61 of the normal N-ras gene was sufficient to activate it (13). Constructions were made (Fig. 3 ) to obtain alternative recombinant entities containing the second exon either from the transformant clone (X3.2 N-rasT) or from a clone isolated from the brain of the animal that developed the tumor. Since the entire transforming gene can be obtained in a Kpn I-Xho I fragment, this piece was made blunt-ended with T4 DNA polymerase and Xho I linkers were attached to both ends. After Xho I digestion and separation of the linkers by gel-permeatioiq chromatography on Sepharose 4B, the N-ras gene was cloned in a pBR derivative containing a single Xho I cloning site (a gift of S. Goff). To substitute the second exon for its equivalent coming from brain DNA, a Bal I-Xba I fragment encompassing the second exon was replaced in the construct (Fig. 3) . The two homologous constructions were used in the 3T3 focus-forming assay and found to be active only when the second exon originated from the transformant gene and not when it originated from the brain gene (Fig. 3) . Therefore, the single base change in codon 61 activates the gene, as shown by its ability to transform NIH 3T3 fibroblasts. Allelic Composition of the N-ras Locus in Tumor and Brain DNA. Activated N-ras genes have been detected in several other thymic lymphomas in addition to the one from which the X3.2 N-rasT clone was derived (18) . The mutation at codon 61 in X3.2 N-rasT altered no known restriction enzyme recognition site, so to test other tumors for the presence of similar mutations, we applied the mismatch hybridization technique, making use of synthetic oligonucleotides and appropriate washing conditions (25, 26) to detect both alleles specifically. We obtained two oligonucleotides, one complementary to the normal sequence (n probe) and the other, to the transforming sequence (t probe). Only DNA from the tumor from which X3.2 N-rasT was obtained hybridized with the t probe (Fig. 4A, lane c) . All other tumors and all brain DNA samples were negative and hence lacked the C--A transversion mutation at codon 61. As a positive control, DNA from 3T3 cells transformed with the N-ras gene from the positive tumor was tested and found to hybridize with the probe, but DNA from untransformed 3T3 cells did not.
Conversely, all other tumors and all brain DNAs hybrid- Washing and autoradiography were as described (25, 26) . The To distinguish between these two possibilities, we hybridized a Southern blot with equal amounts of tumor and brain DNA with probes specific for N-ras and for the dihydrofolate reductase gene (38) , an unlinked gene. Densitometric measurements of nonsaturating autoradiographic exposures showed equal intensities for both genes (data not shown), consistent with the presence of two copies of the mutant N-ras gene per tumor cell.
Krontiris et al. (32) used allelic polymorphism in the human Ha-ras locus (HRAS) to study its variation and content in a significant number of human tumors and tumor cell lines. With this approach, some instability in this locus has been documented with nearly complete loss of an allele in some DNAs. However, no information with regard to the presence of point mutations in the ras genes was provided. The results presented in this report shed some light on two of the questions that need to be addressed in ras oncogene activation. (i) Are ras mutations dominant or recessive? The existence of tumor cell lines that have both normal and mutated alleles (14, 15) would suggest dominance of the mutated allele, but the only such line analyzed at the RNA level showed an expression of the mutated allele increased several-fold (15) . Further, homo-or hemizygosity of the activated allele has been found in tumor cell lines (16, 17) , and we present here evidence for the occurrence of this phenomenon in a primary tumor. This might indicate in vivo selection against the normal allele, consistent with a codominant, or even a recessive, phenotype for the activated N-ras gene. (ii) Are ras mutations an early or late event during tumor development? Two reports on cell lines provide evidence for activation of N-ras during growth of these lines in vitro (33, 34) . We show in this study that in activation in vivo, possible duplication of the mutated gene and loss of the normal allele had to occur early enough in tumor development to give a pure population of cells with those unusual features. Since the tumors in this model system are fully developed in more than 90% of the cases at a fixed time (=4 months), the argument that these alterations occurred late and then gave an advantage to such cells, by enhancing their growth, is in this case more difficult to sustain. With DNA extracted from the active tumorous thymus, the normal allele is below the level of detection, indicating that activation of N-ras alleles had to occur early in tumor development.
It has been implied that ras oncogenes show dominance in cultured rodent fibroblasts (1-4) ; this may, however, be misleading since these oncogenes seem to require a complementing gene (35, 36) or very high expression (37) to transform primary rodent cultures, and even most 3T3 transformants show amplification of the transferred oncogene, suggesting a dose effect (13) . Moreover it has been impossible so far to transform human primary cultures with ras genes in a direct, unambiguous way. The results presented here show that, at least in some cases, selection for cells with a homozygous complement of the mutant gene occurs in vivo and that the loss of the normal allele might be the event required for the expression and consequent selection of a recessive ras mutation.
Note Added in Proof. A recent report (39) described the presence of a consistent mutation, different from the one reported here, in N-nitroso-N-methylurea-induced rat breast carcinomas with an activated Ha-ras. Additional studies in other model systems are needed to clarify the molecular bases of this apparent discrepancy.
